Evidence-based guideline recommendations on the use of positron emission tomography imaging in head and neck cancer from ontario and guidelines in general-some observations

Clinical Oncology

Volumn 25, Issue 4, 2013, Pages 242-245

  Wong, Wai Lup ^a   Ross, P ^a   Corcoran, M ^a  

^a MOUNT VERNON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

BIOMEDICAL TECHNOLOGY ASSESSMENT; CANCER DIAGNOSIS; CANCER PATIENT; CANCER RECURRENCE; CANCER STAGING; CHEMORADIOTHERAPY; CLINICAL DECISION MAKING; COMPUTER ASSISTED EMISSION TOMOGRAPHY; EDITORIAL; EVIDENCE BASED PRACTICE; HEAD AND NECK CANCER; HUMAN; LOCAL RECURRENCE FREE SURVIVAL; NASOPHARYNX CARCINOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECURRENT DISEASE; TAXONOMY;

FLUORODEOXYGLUCOSE F18; HEAD AND NECK NEOPLASMS; HUMANS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS;

EID: 84875365724     PISSN: 09366555     EISSN: 14332981     Source Type: Journal    
DOI: 10.1016/j.clon.2013.01.004     Document Type: Editorial

References (26)

1. Yoo J, Henderson S, Walker-Dyke C. Evidence-based guideline recommendations on the use of positron emission tomography imaging in head and neck cancer.
2. Facey K, Bradbury I, Laking G, Payne E. Overview of the clinical effectiveness of PET imaging in selected cancers. HTA 2007 October 11 [44] iiiiv, xi-267. Available at: http://www.ncchta.org/fullmono/mon1144.pdf.
3. [accessed 5.11.12]. http://www.nice.org.uk/media/62F/36/How_NICE_clinical_guidelines_are_dev.
4. Evidence-based indications for the use of PET CT in the UK 2012 - a joint publication of The Royal College of Physicians and The Royal College of Radiologists.
5. Update to Australia and New Zealand Physicians in Nuclear Medicine referrers' guide to nuclear medicine and PET procedures. PET: Medicare Eligible Items as listed in MBS 1 November 2011.
6. 18F-fluorodeoxyglucose (FDG) PET and PET CT practice guidelines in oncology. PET Professional Resources and Outreach Source, Society of Nuclear Medicine, March 2012.
7. PET und PET CT bei Kopf and Halstumoren. Institut für Qualität und Wirtshaflichkeit im Gesundheitwesen [IQWiG] Berichte Jahr 2011 Nr 82.
8. Greven K.M. PET for head and neck cancer. Semin Radiat Oncol 2004, 14:121-129.
9. Perie S., Hungentobler A., Susini B., et al. Impact of FDG PET to detect recurrence of head and neck squamous cell carcinoma. Otolaryngol Head Neck Surg 2007, 137:647-653.
10. Isles M.G., McConkey M.G., Mehanna H.M. A systematic review and metaanalysis of the role of PET in the follow-up of head and neck cancer following radiotherapy and chemotherapy. Clin Otolaryngol 2008, 33:210-222.
11. Abgral R., Querellou S., Potand G., et al. Does FDG PET CT improve the detection of post treatment recurrence of head and neck carcinoma in patients negative for disease on clinical follow up. J Nucl Med 2009, 50:24-29.
12. Schoder H., Yeung H.W.D., Gonen M., Kraus D., Larson S.M. Head and neck: clinical usefulness and accuracy of PET CT image fusion. Radiology 2004, 231:65-72.
13. Porceddu S.V., Jarmolowski E., Hicks R.J., et al. Utility of PET for the detection of disease in residual neck nodes after [chemo]radiotherapy in head and neck cancer. Head Neck 2005;March, 175.
14. Inohara H., Enomoto K., Tomiyama Y., et al. The role of FDG PET in the managing of node positive head and neck cancer after chemoradiotherapy. Acta Otolaryngol 2009, 129:893-899.
15. Yao M., Smith R.B., Graham M.M., et al. The role of FDG PET in the management of neck metastasis from head and neck cancer after definitive radiation treatment. Int J Radiat Oncol Biol Phys 2005, 63:991-999.
16. Rogers J.W., Greven K.M., McGuirt W.F., et al. Can post-RT neck dissection be omitted for patients with head and neck cancer who have a negative PET scan after definitive radiation therapy?. Int J Radiat Oncol Biol Phys 2004, 58:694-697. 58:307.
17. Nishumura G., Matsuda H., Taguchi T., et al. Treatment evaluation of metastatic lymph nodes after concurrent chemoradiotherapy in patients with head and neck squamous cell carcinoma. Anticancer Res 2012, 32:595-600.
18. Loo S.W., Geropantas K., Beadsmore C., Montgomery P.Q., Martin W.M., Roques T.W. Neck dissection can be avoided after sequential chemo-radiotherapy and negative post treatment PET CT in N2 head and neck cancer. Clin Oncol 2011, 23:512-517.
19. Wang Y.-F., Liu R.-S., Chu P.-Y., et al. PET in surveillance of head and neck squamous cell carcinoma after definitive chemoradiotherapy. Head Neck 2009;April, 442-451.
20. Guyatt G.H., Oxman A.D., Vist G.E., Kunz R., Flack-Ytter Y., Schnumann H.J. GRADE: what is the quality of evidence and why is it important to clinicians?. Br Med J 2008, 336:995.
21. Simon H.A. Administrative behavior 1947, McMillan, New York.
22. Simon H.A. The new science of management decisions 1960, Harper & Row, New York.
23. Miller S.J., Wilson D.C. Perspectives on organized decision making. The handbook of organisation studies 2006, 469-484. Sage, London. 2nd ed. S.R. Clegg, C. Hardy, T.B. Lawrence, W.R. Nord (Eds.).
24. Woolf S.H., Grol R., Hutchinson A., Eccles M., Grimshaw J. Potential benefits, limitations and harms of clinical guidelines. Br Med J 1999, 318:527.
25. Development and validation of an international appraisal instrument for assessing the quality of clinical practice guidelines: the AGREE project. Qual Saf Healthcare 2003, 12:18-23. The AGREE Collaboration.
26. Eccles M.P., Grimshaw J.M. Selecting, presenting and delivering clinical guidelines: are there any -magic bullets. Med J Australia 2004, 180(6):52.